Safety of engineered allergen-specific immunotherapy vaccines
about
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific ImmunotherapyNew vaccines for Mammalian allergy using molecular approachesFood allergies: the basicsSolution and high-pressure NMR studies of the structure, dynamics, and stability of the cross-reactive allergenic cod parvalbumin Gad m 1Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.Cloning, expression, and analysis of a cDNA coding for the Dermatophagoides farinae group 21 (Der f 21) allergen.Mold allergens in respiratory allergy: from structure to therapy.Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B InfectionAn assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.Cow's milk allergy: from allergens to new forms of diagnosis, therapy and prevention.New directions in immunotherapy.Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.Investigational drugs for the treatment of allergic rhinitis.Modified allergens and their potential to treat allergic disease.Advances in patent applications related to allergen immunotherapy.Computational vaccinology and the ICoVax 2012 workshop.Homology modeling and epitope prediction of Der f 33.
P2860
Q26852113-6DD31154-412D-4FC0-8AE0-6B667AD6DEC9Q26998820-02E56841-AB69-48F7-B4A5-84987EDABCB5Q27011839-31BFF3E2-FD3E-4B55-8E8E-A1E1EA12CAD4Q27694772-A2E325BC-6940-4BC2-88A7-C3C2CFD56BB9Q34415246-3846F330-FD06-4526-80C7-403995FA8FB0Q34978803-3130ACEE-BBB6-4DDB-B0F8-441264213926Q35420488-ED931447-C20E-4D0A-9D64-EC3C32FF45D5Q35566610-1A63A98A-20F8-4239-9FAE-F6118BCFC945Q37309327-E8631DE9-2311-44B0-A895-8E95B792F401Q37660273-896AE7F0-A825-46E9-A635-D84028F74545Q37671347-4E8F3BF2-1F62-4A02-B0B8-D9D156B1FB0EQ38073718-BBDE442C-3D86-4590-AF5B-2E0CB3E85EF5Q38112352-693F967F-AFD4-48CE-BB4B-86FCADE0D5BDQ38154958-90379EE3-C852-4A4F-8217-760BFD18526FQ38202695-81F59641-51DF-4309-9283-6C4B764EF732Q38255585-3EA72B18-5386-4435-B243-7D46A5CEAF91Q38787402-0371AAE2-94AE-4265-B843-E8858EA07F5BQ43227656-A683FC82-CF7B-45D9-A814-14AAB6E0841BQ55102636-410399C8-B5E1-45DF-9D28-570DF17BCB9E
P2860
Safety of engineered allergen-specific immunotherapy vaccines
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety of engineered allergen-specific immunotherapy vaccines
@ast
Safety of engineered allergen-specific immunotherapy vaccines
@en
Safety of engineered allergen-specific immunotherapy vaccines
@nl
type
label
Safety of engineered allergen-specific immunotherapy vaccines
@ast
Safety of engineered allergen-specific immunotherapy vaccines
@en
Safety of engineered allergen-specific immunotherapy vaccines
@nl
prefLabel
Safety of engineered allergen-specific immunotherapy vaccines
@ast
Safety of engineered allergen-specific immunotherapy vaccines
@en
Safety of engineered allergen-specific immunotherapy vaccines
@nl
P2860
P3181
P1476
Safety of engineered allergen-specific immunotherapy vaccines
@en
P2093
Margarete Focke-Tejkl
P2860
P304
P3181
P356
10.1097/ACI.0B013E328357CA53
P407
P577
2012-10-01T00:00:00Z